

Name	Structure	Reported target	Company	Approved for clinical use	Name	Structure	Reported target	Company	Approved for clinical use	Name	Structure	Reported target	Company	Approved for clinical use
Fasudil (Eri)		ROCK1/2	Asahi Kasei	1995 cerebral vasospasm PAH	Trametinib		MEK1/2	GSK	2013 skin cancer	Binimetinib		MEK RAF	ARRAY Novartis	2018 melanoma
Sirolimus (Rapamune)		mTOR	Wyeth Pfizer	1999 kidney transplantation	Afatinib		HER2 EGFR	Bi	2013 NSCLC with EGFR mutations	Duvulsiib		PI3K δ/γ	Infinity Verastem	2018 CLL SLL
Imatinib		Bcr-Abl c-KIT PDGFR	Novartis	2001 chronic myelogenous leukemia	Ibrutinib		Bruton's Tyrosine Kinase	Janssen Pharmaceutic	2013 mantle cell lymphoma, CLL	Dacomitinib		EGFR	Pfizer	2018 NSCLC with EGFR mutations
Gefitinib		EGFR	AZ	2003 NSCLC	Ripasudil		ROCK	Kowa	2014 glaucoma ocular hypertension	Gilteritinib		FLT3 AXL	Astellas	2018 acute myeloid leukemia
Erlotinib		EGFR	Genetech Roche	2004 NSCLC pancreatic cancer	Ceritinib		ALK	Novartis	2014 NSCLC with ALK translocations	Larotrectinib		NTRK	LOXO Bayer	2018 cancer with NTRK fusions
Sorafenib		Multiple Tyrosine kinases targeted	Onyx Bayer	2005 renal cancer HCC	Idelalisib		PI3K δ	Gilead, Calistoga, ICOS	2014 chronic lymphocytic leukemia, FL	Catequentinib		VEGFRs	Advenchen	2018 NSCLC
Sunitinib		Multiple Tyrosine-kinases targeted	Sugen Pfizer	2006 renal cancer, Imatinib resistant GIST	Nintedanib		VEGFR PDGFR FGR	Bi	2014 idiopathic pulmonary fibrosis	Lorlatinib		ALK ROS	Pfizer	2018 NSCLC
Dasatinib		Multiple Tyrosine-kinases targeted	BMS	2006 chronic myelogenous leukemia ,ALL	Alectinib		ALK	Roche, Chugai	2014 NSCLC with ALK translocations	Fostamatinib		SYK	Rigel	2018 autoimmune thrombocytopenia
Lapatinib		EGFR ERBB2	GSK	2007 breast cancer	Palbociclib		CDK4/6	Pfizer	2015 advanced (metastatic) breast cancer	Erdafitinib		FGFR	Astex Janssen	2019 urothelial cancer
Nilotinib		Bcr-Abl	Novartis	2007 chronic myelogenous leukemia	Lenvatinib		VEGFRs	Eisai	2015 thyroid cancer (DTC), kidney cancer	Alpelisib		PI3Kα	Novartis	2019 breast cancer
Temsirolimus		mTOR	Wyeth Pfizer	2007 advanced renal cell carcinoma	Cobimetinib		MEK	Roche, Exelixis	2015 melanoma	Peixidartinib		CSF1R c-KIT	Plexikon	2019 TGCT
Everolimus		mTOR	Novartis	2009 renal cell carcinoma	Osimertinib		EGFR	AZ	2015 NSCLC with EGFR mutation	Entrectinib		TRK ROS ALK	Ignitya Roche	2019 NSCLC
Pazopanib		VEGFR2 PDGFR c-KIT	GSK	2009 renal cancer	Olumetinib		EGFR	Bi	2016 NSCLC with EGFR mutation	Upadactinib		JAK	AbbVie	2019 rheumatoid arthritis
Crizotinib		ALK MET	Pfizer	2011 NSCLC with ALK mutation	Ribociclib		CDK4/6	Novartis	2017 advanced (metastatic) breast cancer	Fedratinib		JAK	Celgene	2019 myelofibrosis
Vandetanib		Multiple Tyrosine kinases targeted	AZ	2011 thyroid cancer	Brigatinib		ALK EGFR	Ariad	2017 NSCLC with EGFR mutation	Umbralisib		PI3Kδ	TG Therapeutic	2019 marginal zone lymphoma
Ruxolitinib		JAKs	Incyte Novartis	2011 myelofibrosis	Midostaurin		FLT3 KIT	Novartis	2017 acute myeloid leukemia mastocytosis	Zanubrutinib		Bruton's Tyrosine Kinase	Beigene	2019 mantle cell lymphoma
Vemurafenib		BRAF	Roche Plexikon	2011 metastatic melanoma BRAFV600E	Neratinib		EGFR	Wyeth Pfizer	2017 breast cancer HER2	Leniolisib		PI3Kδ	Novartis	2019 APDS PASLI disease
Axitinib		VEGFRs PDGFRB c-KIT	Pfizer	2012 renal cell carcinoma	Baricitinib		JAKs	Incyte Eli Lilly	2017 rheumatoid arthritis	Avapritinib		PDGFR KIT	Blueprint	2020 GIST
Regorafenib		VEGFR2 TIE2 others PTKs	Bayer	2012 colorectal cancer GIST, HCC	Abemaciclib		CDK4/6	Eli Lilly	2017 advanced (metastatic) breast cancer	Tucatinib		HER2	ARRAY Oncology	2020 HER2 breast cancer
Tofacitinib		JAKs	Pfizer	2012 rheumatoid arthritis	Copanlisib		PI3K mTOR	Bayer	2017 follicular lymphoma	Pemigatinib		FGFR2	Incyte	2020 cholangiocarcinoma with FGFR2 fusion
Cabozantinib		VEGFR2 PDGFR KIT	Exelixis	2012 medullary thyroid cancer	Netarsudil		ROCK	Aerie	2017 glaucoma (topical)	Tabrecta		MET	Novartis	2020 mNSCLC with ex14 mutation
Ponatinib		SRC Abl	Ariad	2012 chronic myelogenous leukemia, ALL	Tivozanib		VEGFR	EUSA Pharma	2017 RCC	Selpercatinib		RET	Eli Lilly	2020 NSCLC MTC, thyroid cancers
Bosutinib		Bcr-Abl SRC	Pfizer	2012 chronic myelogenous leukemia	Acalabrutinib		Bruton's Tyrosine Kinase	AZ Certara Pharma	2017 mantle cell lymphoma, CLL	Ripretinib		KIT	Deciphera	2020 GIST Mastocytosis
Radotinib		Bcr-Abl PDGFR	Daewoong	2012 chronic myelogenous leukemia	Simotinib		EGFR	Jiangsu Sincare Pharm.	2018 NSCLC	Paxalisib		PI3K mTOR	Kazia Therapeutics	2020 Glioblastoma
Dabrafenib		BRAF	GSK	2013 skin cancer	Encorafenib		MEK RAF	ARRAY Novartis	2018 melanoma	Pralsetinib		RET	Blueprint Roche	2020 NSCLC thyroid cancers